Oncorus to Participate in Fireside Chats at Upcoming Piper Sandler Annual Healthcare Conference and Evercore ISI HealthCONx Conference

Rhea-AI Summary

Oncorus, Inc. (Nasdaq:ONCR) announced that CEO Theodore A. Ashburn will participate in two investor conferences. The 32nd Annual Piper Sandler Virtual Healthcare Conference runs from December 1-3, 2020, with a pre-recorded presentation available online. Additionally, Ashburn will present live at the 3rd Annual Evercore ISI HealthCONx Conference on December 3, 2020, at 9:40 a.m. ET. Oncorus is focused on innovative viral immunotherapies for cancer treatment, including its lead program, ONCR-177, aimed at enhancing therapeutic impact while minimizing systemic toxicity.

CAMBRIDGE, Mass., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq:ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, announced today that Theodore (Ted) A. Asbhurn, M.D., Ph.D., President and Chief Executive Officer, will participate in fireside chats at two upcoming investor conferences.

32^nd Annual Piper Sandler Annual Virtual Healthcare Conference
Dates: December 1 - December 3, 2020
Webcast: The pre-recorded fireside chat is now available in the Investors & Media section of Oncorus’ website at https://investors.oncorus.com/events-and-presentations. The presentation will be archived on the company’s site for 90 days.

3rd Annual Evercore ISI HealthCONx Conference
Date: December 3, 2000
Time: 9:40 a.m. ET
Webcast: A live webcast of the presentation will be available in the Investors & Media section of Oncorus’ website at https://investors.oncorus.com/events-and-presentations. A replay of the presentation will be archived on the company’s site.

About Oncorus

At Oncorus, we are focused on driving innovation to deliver next-generation viral immunotherapies to transform outcomes for cancer patients. We are advancing a portfolio of intratumorally and intravenously administered viral immunotherapies for multiple indications with significant unmet needs based on our oncolytic Herpes Simplex Virus (oHSV) Platform and Synthetic Virus Platform. Designed to deliver next-generation viral immunotherapy impact, our oHSV platform improves upon key characteristics of this therapeutic class to enhance potency without sacrificing safety, including greater capacity to encode transgenes to drive systemic immunostimulatory activity, retention of full replication competency to enable high tumor-killing potency, and orthogonal safety strategies to restrict viral activity in tumor cells. Our lead oHSV program, ONCR-177, is designed to be directly administered into a tumor, resulting in high local concentrations of the therapeutic agent, as well as low systemic exposure to the therapy, which we believe could potentially limit systemic toxicities. Please visit www.oncorus.com to learn more.

Investor Contact:	Media Contact:
Alan Lada	Liz Melone
Solebury Trout	liz.melone@oncorus.com
617-221-8006
alada@soleburytrout.com

FAQ

When will Oncorus participate in investor conferences?

Oncorus will participate in the 32nd Annual Piper Sandler Virtual Healthcare Conference from December 1-3, 2020, and the 3rd Annual Evercore ISI HealthCONx Conference on December 3, 2020.

What is the time of Oncorus's presentation at the Evercore ISI HealthCONx Conference?

The live presentation by Oncorus at the Evercore ISI HealthCONx Conference is scheduled for December 3, 2020, at 9:40 a.m. ET.

Where can I watch Oncorus's investor presentations?

Investor presentations by Oncorus can be found in the Investors & Media section of their website, with recordings archived for 90 days.

What is Oncorus's lead cancer therapy program?

Oncorus’s lead program is ONCR-177, designed to be administered directly into tumors for effective localized treatment.

What innovative platforms does Oncorus utilize for cancer therapies?

Oncorus utilizes the oncolytic Herpes Simplex Virus (oHSV) Platform and Synthetic Virus Platform for their viral immunotherapies.